When FA‐BSA was used to achieve dynamically targeted drug delivery, drug accumulation was increased in tumor tissues, and synergistic treatment markedly enhanced the anticancer effect.[54] CuS‐ATMi@TGF‐NPs, loaded with ataxia‐telangiectasia mutated (ATM) inhibitors, could actively target tumors with an anti‐TGF antibody and substantially reduce tumor development. This evidence concerns the gene ATM and neoplasm.